# Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

> **NCT00499707** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 453 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** rosiglitazone maleate/metformin hydrochloride

## Key facts

- **NCT ID:** NCT00499707
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10-08
- **Primary completion:** 2004-12-01
- **Final completion:** 2004-12-16
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499707, "Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00499707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*